NFE2L2 and Parkinson disease: Similarly, a recent report showed a novel therapeutic candidate ALGERNON2 (altered generation of neurons 2) reduced the proinflammatory cytokines secretion and stabilized cyclinD1/p21 complex by inhibiting Dyrk1A activity, leading to Nrf2-dependent antioxidant and anti-inflammatory responses in a MPTP-induced PD model (Kobayashi et al., 2016).